In its Corporate Responsibility Report published today, GSK reiterated its commitment to running its business responsibly and transparently. GSK provided an update on how it will work to improve access to medicines in the developing world and further details about initiatives outlined in February. The company announced additional steps to build on its commitment to the transparency of clinical research data and the public disclosure of its financial interactions with healthcare professionals. It also reported a substantive increase in its level of charitable support.

Commenting on the report, Andrew Witty, CEO of GlaxoSmithKline said: “We recognise that GSK has unique and privileged capabilities. Continually strengthening our contract with society is vitally important and this is why we are fully committed to operating to the highest ethical standards. This report emphasises our determination to do just that - whether it is by cutting prices in the world's poorest countries, being more flexible with our intellectual property to encourage more research into neglected diseases, or increasing transparency to facilitate clinical research. As we move forward, we will continue to look for new ways and new partnerships to improve global public health and research."....계속